You need to enable JavaScript to run this app.
Recon: VA declines to cover Biogen's Aduhelm; FDA rejects Fibrogen anemia drug
Recon
Michael Mezher
Biologics/ biosimilars/ vaccines
Biotechnology
Diagnostics/IVDs
Global
Medical Devices
North America
Pharmaceuticals
Regulatory Intelligence/Policy